YUSIMRY™ (adalimumab-aqvh) - list price $995 per carton of two 40 mg/0.8 mL autoinjectorsSee https://www.yusimry.com for YUSIMRY™ Full Prescribing Information, including Boxed Warning and Medication ...
Despite being the seventh adalimumab biosimilar approved in the United States, there are none on the market yet. The FDA has approved a seventh adalimumab biosimilar, Yusimry, which is developed by ...
Please provide your email address to receive an email when new articles are posted on . Coherus’ adalimumab biosimilar, Yusimry, will enter the U.S. market in July at an 85% discount from AbbVie’s ...
The pharmacy benefit manager SmithRx has announced that through a partnership with the Mark Cuban Cost Plus Drug Company, it will offer Yusimry, an adalimumab biosimilar, for less than 90% of the cost ...
YUSIMRY™ (adalimumab-aqvh) - list price $995 per carton of two 40 mg/0.8 mL autoinjectorsSee https://www.yusimry.com for YUSIMRY™ Full Prescribing Information, including Boxed Warning and Medication ...
Adalimumab is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and ...
REDWOOD CITY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (CHRS) (“Coherus”, Nasdaq: CHRS) and specialty pharmacy Superior Biologics, Inc. (“Superior Biologics”) today ...
AbbVie Inc (NYSE:ABBV) has challenged Coherus BioSciences Inc (NASDAQ:CHRS), alleging Coherus breached its settlement and license agreement after it announced its plans to launch Yusimry, a biosimilar ...
DALLAS, Texas and REDWOOD CITY, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Mark Cuban Cost Plus Drug Company, PBC (“Cost Plus Drugs” or “Mark Cuban Cost Plus Drug Company”) and Coherus BioSciences, Inc ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved the seventh biosimilar to adalimumab, adalimumab-aqvh, for all eligible indications of the ...
REDWOOD CITY, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) announced that the United ...
REDWOOD CITY, Calif., July 03, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (CHRS), today announced that YUSIMRY™ (adalimumab-aqvh) is now available for commercial sale in the United States at a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results